Haircare, Salon Trends and Hair-Loss Science — October 3, 2026
Scalp care is emerging as a major market category with premium serums and medicated treatments driving growth through 2035, while Asian beauty brands launch innovative formulas targeting scalp biology. Simultaneously, clinical progress on hair-loss drugs accelerates with multiple JAK inhibitor approvals and Phase 3 trials planned for new topical candidates, reshaping treatment options for alopecia areata and androgenetic alopecia.
Haircare, Salon Trends and Hair-Loss Science — October 3, 2026
Top developments
Global Scalp Care Market Expands on Premium Serum Demand
The worldwide scalp care market is set to accelerate through 2035, fueled by rising consumer demand for premium serums and medicated dandruff treatments as scalp health moves from niche concern to mainstream priority. Premium multi-step routines and preventative scalp biology focus are driving category expansion, with brands investing in diagnostic tools and personalized formulations.
Japan Launches Bond-Repair and Scalp Serum Innovations
MTG's health and fitness brand SIXPAD debuted its first haircare line on September 29, launching three items designed to "train" hair with a focus on structural integrity. The line rolls out to Rakuten on October 13, followed by MTG's official store and Amazon on November 18. Concurrently, Mermood released a new hydro-change treatment formula on October 1 targeting moisture and shine without weight.
South Korea's Cosmax Develops AI-Driven Alopecia Areata Prediction Model
Cosmax, a global cosmetics ODM firm, announced completion of a patent application for an AI-based alopecia areata risk prediction model trained on 22 million data points from health screenings in South Korea and Japan. The model enables early intervention targeting and has driven haircare revenue growth of 65% at Shinsegae duty-free counters. Cosmax is expanding research into multiethnic scalp analysis and damaged-hair materials.
Korea's ABiomaterials Unveils Dual-Action Hair Booster with AAPE and PDRN
ABiomaterials launched Cerexo AAPE, a two-part haircare booster combining freeze-dried powder and solution ampoule for on-demand mixing. The formula incorporates AAPE 3.1, olive-derived PDRN, and plant botanicals targeting both scalp conditioning and hair fiber integrity. The product reflects growing market demand for multi-targeted scalp and hair systems.
JAK Inhibitor Pipeline Expansion for Alopecia Areata Accelerates
Three JAK inhibitors have received FDA approval in rapid succession: Olumiant (baricitinib) in 2022, Litfulo (ritlecitinib) in 2023, and Leqselvi (deuruxolitinib) in 2024, marking unprecedented clinical progress in alopecia areata treatment. PP405, a topical JAK inhibitor candidate, demonstrated primary safety in a 78-patient Phase 2a trial with no detectable systemic absorption and exploratory density gains in higher-severity male subgroups; Phase 3 initiation is planned for 2026.
Local view
Japan (FashionSnap): Japanese beauty media emphasizes ingredient-led innovation and scalp biology research as the foundation for 2026 haircare launches. SIXPAD's entry reflects broader Japanese brand strategy to position haircare as performance-driven, mirroring fitness and wellness messaging.
Korea (E-Today, Seoul Economic Daily): Korean stakeholders highlight AI-driven personalization and scalp diagnostics as competitive advantages. Cosmax's patent filing and ABiomaterials' multicomponent formulations signal a shift toward precision medicine in beauty, with duty-free retailers reporting strong consumer uptake of premium scalp serums.
Context & numbers
- Global scalp care market: Forecast to expand through 2035 driven by premiumization and preventative health demand.
- Cosmax haircare revenue: Up 65% at Shinsegae duty-free, signaling strong retail momentum in Asia-Pacific.
- JAK inhibitor approvals: Three drugs approved in three years (2022–2024) for alopecia areata, followed by Phase 3 planning for topical candidates in 2026.
- Market segment shift: Scalp care now positioned as a distinct category comparable to facial skincare, with diagnostic tools and multi-step routines becoming standard consumer expectations. [Sources: ; ; https://www.dermatologytimes.com/view/faq-everything-clinicians-and-their-patients-want-to-know-about-the-hair-loss-pipeline]
On the radar
-
Dyson Airsmooth launch: Dyson's new entry-level hot brush (£199.99 / ~$250 USD) positioned as affordable alternative to Airwrap, signaling intensifying competition in premium styling tools. Shark's FlexStyle IonCurl continues as budget-conscious challenger.
-
Phase 3 trial momentum: Multiple exosome and stem cell therapy trials approaching Phase 3 completion; topical candidates (PP405) entering Phase 3 in 2026 signal potential regulatory approvals by late 2026–2027.
-
Bond-repair category maturation: Vogue and industry analysts flag bond-repair and keratin-mask formulations as stabilizing after 2025 hype cycle; differentiation shifting to scalp health and multimodal damage repair.
-
Scalp diagnostics adoption: AI-powered scalp analysis tools (Cosmax model, routine health data integration) expected to expand in South Korea and Japan through 2027, with potential adoption in North America and Europe by 2028.
Sources cited:
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
